` 2256 (Abbisko Cayman Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

2256
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, Abbisko Cayman Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +218% compared to the Hang Seng (Hong Kong)'s +34% growth.

Stocks Performance
2256 vs Hang Seng (Hong Kong)

Loading
2256
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com

Performance Gap
2256 vs Hang Seng (Hong Kong)

Loading
2256
Hang Seng (Hong Kong)
Difference
www.alphaspread.com

Performance By Year
2256 vs Hang Seng (Hong Kong)

Loading
2256
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
Abbisko Cayman Ltd vs Peers

Hang Seng (Hong Kong)
2256
ABBV
AMGN
GILD
VRTX
Add Stock

Abbisko Cayman Ltd
Glance View

Market Cap
7.2B HKD
Industry
Biotechnology

Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Intrinsic Value
2.99 HKD
Overvaluation 71%
Intrinsic Value
Price
Back to Top